Cure8 trial brief
Researchers planned to study whether patterns in the gut microbiome correlate with clinical diagnoses (including Crohn’s and UC), which could inform future biomarker work. The study is suspended, so no results are available from this record.
Researchers in microbiome and biomarker discovery; patients with Crohn’s disease or ulcerative colitis and their caregivers; clinicians following microbiome research.
This study is observational (no intervention). Researchers planned to sequence stool microbiomes and analyze relative abundance of bacterial taxa, then look for correlations with self-reported and medical-recorded disease categories, including Crohn’s disease and ulcerative colitis.
The record lists broad eligibility (age ≥12, many exclusions such as prior colectomy or ostomy) and a one-year time frame for the primary outcome. The listing is marked SUSPENDED; that means recruitment or study activities were paused and results are not reported here.
Because this is a trial registry entry, it describes planned methods rather than published findings.
This is a clinicaltrials.gov registration describing planned observational methods (stool sequencing, relative abundance analysis) rather than a published study with results. The record is listed as SUSPENDED, indicating the study was paused.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Vitamin D appears linked to immune regulation, gut barrier health, and the microbiome—processes relevant to IBD and other intestinal disorders. Understanding this could affect how clinicians monitor and study vitamin D...
Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.
